41 reports

  • SEGMENTATION OF TYPE 1 DIABETES DRUGS MARKET BY DRUG CLASS
  • TYPE 1 DIABETES DRUGS MARKET IN AMERICAS 2015-2020 ($ BILLIONS)

About Type 1 Diabetes Drugs Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types: - Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading...

  • Type 1 Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Global Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Forecast

Type ## Diabetes Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • APAC
  • World
  • Demand

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Market Shares
  • Market Size

Europe Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 1 Diabetes
  • Europe
  • France
  • Germany
  • Forecast
  • TOP-LINE PREVALENCE FOR TYPE 1 DIABETES MELLITUS
  • Prevalence of Type 1 Diabetes Mellitus, total (000s)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 1 Diabetes Mellitus in 12 Major Markets Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas’ ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to...

  • Chronic Disease
  • Diabetes
  • Pathology
  • Type 1 Diabetes

Type ## Diabetes (T##D) Market Size, Forecast And Trend Analysis, 2014 - 2024 Chapter ##.

  • Insulin
  • Therapy
  • Type 1 Diabetes
  • United States
  • Forecast
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 11.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS

PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Japan
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • United States
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • United Kingdom
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • France
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Germany
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Italy
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Spain
  • Market Size
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS

Type 1 Diabetes - US Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014

Type 1 Diabetes - Japan Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014

Type 1 Diabetes - Canada Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014

Type 1 Diabetes - 5EU Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 5.4.1 Diagnosed Type 1 Diabetes Patients
  • SALES FOR TYPE 1 DIABETES IN CANADA BY DRUG CLASS, 2013-2023

Type 1 Diabetes - Current and Future Players Summary GlobalData has released its pharma report, “Type 1 Diabetes - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Insomnia Market. The report identifies and analyses the key...

  • Type 1 Diabetes
  • Canada
  • North America
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • North America Insulin Pumps Market, By Value
  • Europe Insulin Pumps Market, By Value

Insulin Pumps Outlook Type I Diabetes: Type I diabetes is an autoimmune disease that destroys the insulin producing beta cells in the pancreas of the human body.

  • Insulin Delivery
  • Type 1 Diabetes
  • World
  • Market Size
  • Animas Corporation

Drug analysis: Farxiga

9091 10000 7727

Drug analysis: Farxiga PRODUCT PROFILES Farxiga : Diabetes type ## Farxiga : Diabetes type ## LIST OF FIGURES Figure ##: Farxiga for type ## diabetes – SWOT analysis Figure ##: Datamonitor Healthcare drug assessment of Farxiga Figure ##: Datamonitor Healthcare drug assessment scorecard

  • Diabetes
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 1 Diabetes
  • European Union
  • United States
  • VACCINE FOR TYPE 1 DIABETES - DRUG PROFILE
  • TYPE 1 DIABETES (JUVENILE DIABETES)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape. Type...

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Company

The report focuses on drugs and therapies being evaluated for Type ## Diabetes (Juvenile Diabetes) treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes

Type ## Diabetes Pipeline Highlights – 2017 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • Product Initiative
  • Type 1 Diabetes
  • Inflammatory Bowel disease Type 1 Diabetes Thyroid Others

Autoimmune Disease Diagnostics Market The global autoimmune disease diagnostics market is expected to reach USD XXmillion by 2022 from USD XXmillion in 2016. During this period, the CAGR is expected to reach around XX%. There is an increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies coupled with...

  • Immunochemistry Test
  • Type 1 Diabetes
  • World
  • Market Size
  • Thermo Fisher Scientific, Inc.
  • 03/29/2018: EMA to Review Sotagliflozin as Potential Treatment for type 1 diabetes
  • 06/10/2017: Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017

Summary Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases.The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin (LX4211)...

  • Pharmaceutical
  • Therapy
  • Type 1 Diabetes
  • United States
  • Lexicon Pharmaceuticals, Inc.
  • Type 1 diabetes (Juvenile Diabetes)
  • Type 1 diabetes (Juvenile Diabetes)

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is...

  • Biotechnology
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Company
  • Product Initiative
  • 05/22/2017: JDRF AND VIACYTE ANNOUNCE SUPPORT FOR DEVELOPMENT OF PEC-DIRECT CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES
  • 05/22/2017: JDRF AND VIACYTE ANNOUNCE SUPPORT FOR DEVELOPMENT OF PEC-DIRECT CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES

Summary ViaCyte Inc (ViaCyte), formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes.The company’s pipeline products portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing...

  • Cell Therapy
  • Type 1 Diabetes
  • United States
  • Company Operations
  • ViaCyte, Inc.